Ezetimibe ameliorates metabolic disorders and microalbuminuria in patients with hypercholesterolemia

Journal of Atherosclerosis and Thrombosis

Volumn 17, Issue 2, 2010, Pages 173-180

  Yagi, Shusuke ^a   Akaike, Masashi ^a   Aihara, Ken Ichi ^a   Iwase, Takashi ^a   Ishikawa, Kazue ^a   Yoshida, Sumiko ^a   Sumitomo Ueda, Yuka ^a   Kusunose, Kenya ^a   Niki, Toshiyuki ^a   Yamaguchi, Koji ^a   Koshiba, Kunihiko ^a   Hirata, Yoichiro ^a   Dagvasumberel, Munkhbaatar ^a   Taketani, Yoshio ^a   Tomita, Noriko ^a   Yamada, Hirotsugu ^a   Soeki, Takeshi ^a   Wakatsuki, Tetsuzo ^a   Matsumoto, Toshio ^a   Sata, Masataka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Chronic kidney disease; Inflammation; Metabolic syndrome; Oxidative stress

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; ALBUMIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NITRATE; NITRITE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DIET THERAPY; DRUG EFFECT; FEMALE; HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INFLAMMATION; INSULIN RESISTANCE; JAPANESE; MALE; METABOLIC DISORDER; MICROALBUMINURIA; MORNING DOSAGE; OXIDATIVE STRESS; URINARY EXCRETION; WAIST CIRCUMFERENCE;

EID: 77649196152     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.2378     Document Type: Article

References (26)

1. Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE I and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet, 2001; 357: 995-1001
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497
3. Igel M, Sudhop T, von Bergmann K: Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol, 2001; 57: 357-364
4. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM: Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP writing group recommendations. Am J Cardiol, 2005; 96: 556-563
5. Altmann SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, Graziano MP: Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science, 2004; 303: 1201-1204
6. Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA, Braun MP, Crona JH, Davis HR Jr, Dean DC, Detmers PA, Graziano MP, Hughes M, Macintyre DE, Ogawa A, O'Neill KA, Iyer SP, Shevell DE, Smith MM, Tang YS, Makarewicz AM, Ujjainwalla F, Altmann SW, Chapman KT, Thornberry NA: The target of ezetimibe is Niemann-Pick C1-like 1 (NPC1L1). Proc Natl Acad Sci USA, 2005; 102: 8132-8137
7. Rikitake Y, Liao JK: Rho GTPases, statins, and nitric oxide. Circ Res, 2005; 97: 1232-1235
8. Yagi S, Aihara K, Ikeda Y, Sumitomo Y, Yoshida S, Ise T, Iwase T, Ishikawa K, Azuma H, Akaike M, Matsumoto T: Pitavastatin, an HMG-CoA reductase inhibitor, exerts eNOS-independent protective actions against angiotensin II induced cardiovascular remodeling and renal insufficiency. Circ Res, 2008; 102: 68-76
9. Node K, Fujita M, Kitakaze M, Hori M, Liao JK: Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation, 2003; 108: 839-843
10. Davidson MH, McGarry T, Bettis R, Melani L, Lipka LJ, LeBeaut AP, Suresh R, Sun S, Veltri EP: Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol, 2002; 40: 2125-2134
11. Miettinen TA, Gylling H, Lindbohm N, Miettinen TE, Rajaratnam RA, Relas H: Finnish Treat-to-Target Study Investigtors Serum noncholesterol sterols during inhibition of cholesterol synthesis by statins. J Lab Clin Med, 2003; 141: 131-137
12. Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J: A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc, 2005; 80: 587-595
13. Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J: Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: Subanalyses of data from a randomized, double-blind, placebo-controlled trial. Am J Geriatr Pharmacother, 2005; 3: 218-228
14. Davis HR, Veltri EP: Zetia: inhibition of Niemann-Pick C1 Like 1 (NPC1L1) to reduce intestinal cholesterol absorption and treat hyperlipidemia. J Atheroscler Thromb, 2007; 14: 99-108
15. Alberti KG, Zimmet P, Shaw J IDF Epidemiology Task Force Consensus Group: The metabolic syndrome--a new worldwide definition. Lancet, 2005; 366: 1059-1062
16. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med, 2004; 351: 1296-1305
17. Touyz RM: Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension, 2004; 44: 248-252
18. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res, 2000; 87: 840-844
19. Majid DS, Kopkan L: Nitric oxide and superoxide interactions in the kidney and their implication in the development of salt-sensitive hypertension. Clin Exp Pharmacol Physiol, 2007; 34: 946-952
20. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, Nakayama O, Makishima M, Matsuda M, Shimomura I: Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest, 2004; 114: 1752-1761
21. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, Fung C, Karim R, Lin R, Samarasinghe D, Liddle C, Weltman M, George J: NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-379
22. De Taeye BM, Novitskaya T, McGuinness OP, Gleaves L, Medda M, Covington JW, Vaughan DE: Macrophage TNF-alpha contributes to insulin resistance and hepatic steatosis in diet-induced obesity. Am J Physiol Endocrinol Metab, 2007; 293: E713-725
23. Kotronen A, Juurinen L, Hakkarainen A, Westerbacka J, Corner A, Bergholm R, Yki-Järvinen H: Liver fat is increased in type 2 diabetic patients and underestimated by serum alanine aminotransferase compared with equally obese nondiabetic subjects. Diabetes Care, 2008; 31: 165-169
24. Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, Kechagias S: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology, 2006; 44: 865-873
25. Tabuchi M, Inoue K, Usui-Kataoka H, Kobayashi K, Teramoto M, Takasugi K, Shikata K, Yamamura M, Ando K, Nishida K, Kasahara J, Kume N, Lopez LR, Mitsudo K, Nobuyoshi M, Yasuda T, Kita T, Makino H, Matsuura E: The association of C-reactive protein with an oxidative metabolite of LDL and its implication in atherosclerosis. J Lipid Res, 2007; 48: 768-781
26. Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, Okazaki M, Ishii H, Yoshida M: Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome. FEBS Lett, 2007; 581: 5664-5670